These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15467469)

  • 1. TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability.
    Sim KG; Zang Z; Yang CM; Bonventre JV; Hsu SI
    Cell Cycle; 2004 Oct; 3(10):1296-304. PubMed ID: 15467469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1.
    Hsu SI; Yang CM; Sim KG; Hentschel DM; O'Leary E; Bonventre JV
    EMBO J; 2001 May; 20(9):2273-85. PubMed ID: 11331592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer.
    Zang ZJ; Sim KG; Cheong JK; Yang CM; Yap CS; Hsu SI
    Cancer Biol Ther; 2007 May; 6(5):712-8. PubMed ID: 17507796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression.
    Sim KG; Cheong JK; Hsu SI
    Cell Cycle; 2006 May; 5(10):1111-5. PubMed ID: 16721052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7.
    Xu Y; Sengupta T; Kukreja L; Minella AC
    J Biol Chem; 2010 Nov; 285(45):34439-46. PubMed ID: 20826802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.
    Caldon CE; Sergio CM; Sutherland RL; Musgrove EA
    Cell Cycle; 2013 Feb; 12(4):596-605. PubMed ID: 23324394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators.
    Morris L; Allen KE; La Thangue NB
    Nat Cell Biol; 2000 Apr; 2(4):232-9. PubMed ID: 10783242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated view of cyclin E function and regulation.
    Siu KT; Rosner MR; Minella AC
    Cell Cycle; 2012 Jan; 11(1):57-64. PubMed ID: 22186781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.
    Lerner M; Lundgren J; Akhoondi S; Jahn A; Ng HF; Akbari Moqadam F; Oude Vrielink JA; Agami R; Den Boer ML; Grandér D; Sangfelt O
    Cell Cycle; 2011 Jul; 10(13):2172-83. PubMed ID: 21597324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of PP2A as a novel interactor and regulator of TRIP-Br1.
    Zang ZJ; Gunaratnam L; Cheong JK; Lai LY; Hsiao LL; O'Leary E; Sun X; Salto-Tellez M; Bonventre JV; Hsu SI
    Cell Signal; 2009 Jan; 21(1):34-42. PubMed ID: 18940248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation.
    Bhaskaran N; van Drogen F; Ng HF; Kumar R; Ekholm-Reed S; Peter M; Sangfelt O; Reed SI
    Mol Cell Biol; 2013 Jan; 33(1):85-97. PubMed ID: 23109421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation.
    Hayashi R; Goto Y; Ikeda R; Yokoyama KK; Yoshida K
    J Biol Chem; 2006 Nov; 281(47):35633-48. PubMed ID: 16984923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1.
    Gupta S; Takhar PP; Degenkolbe R; Koh CH; Zimmermann H; Yang CM; Guan Sim K; Hsu SI; Bernard HU
    Virology; 2003 Dec; 317(1):155-64. PubMed ID: 14675634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
    Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
    Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRM1-mediated nuclear export is required for 26 S proteasome-dependent degradation of the TRIP-Br2 proto-oncoprotein.
    Cheong JK; Gunaratnam L; Hsu SI
    J Biol Chem; 2008 Apr; 283(17):11661-76. PubMed ID: 18316374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.
    Ekholm-Reed S; Spruck CH; Sangfelt O; van Drogen F; Mueller-Holzner E; Widschwendter M; Zetterberg A; Reed SI
    Cancer Res; 2004 Feb; 64(3):795-800. PubMed ID: 14871801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E3 ubiquitin ligase FBW7α inhibits cholangiocarcinoma cell proliferation by downregulating c-Myc and cyclin E.
    Li M; Ouyang L; Zheng Z; Xiang D; Ti A; Li L; Dan Y; Yu C; Li W
    Oncol Rep; 2017 Mar; 37(3):1627-1636. PubMed ID: 28184929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors.
    Cheong JK; Gunaratnam L; Zang ZJ; Yang CM; Sun X; Nasr SL; Sim KG; Peh BK; Rashid SB; Bonventre JV; Salto-Tellez M; Hsu SI
    J Transl Med; 2009 Jan; 7():8. PubMed ID: 19152710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.
    Ou B; Zhao J; Guan S; Wangpu X; Zhu C; Zong Y; Ma J; Sun J; Zheng M; Feng H; Lu A
    Cancer Lett; 2016 Oct; 380(2):457-466. PubMed ID: 27423313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells.
    Chen Q; Ross AC
    Exp Cell Res; 2004 Jul; 297(1):68-81. PubMed ID: 15194426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.